Cargando…
Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interp...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550791/ https://www.ncbi.nlm.nih.gov/pubmed/16542472 http://dx.doi.org/10.1186/cc3991 |